Literature DB >> 2784965

Antiproliferative effects of methotrexate on peripheral blood mononuclear cells.

N J Olsen1, L M Murray.   

Abstract

Methotrexate was added to cultured mononuclear cells from the peripheral blood of normal individuals and patients with rheumatoid arthritis (RA) to study the drug's effects on mononuclear cell proliferation and antibody synthesis. In the presence of methotrexate, marked antiproliferative effects (to levels less than 15% of baseline) were seen with 3H-deoxyuridine, but not with 3H-thymidine, as the marker of cell division. This difference was not due to altered kinetics of proliferation or the presence of salvage nucleotides in the culture medium. The absence of suppression of antibody production preactivated by pokeweed mitogen in vitro and the low levels of suppression of spontaneous IgM rheumatoid factor production by blood mononuclear cells from RA patients suggested a relative resistance of activated cells to the effects of methotrexate. The effects of methotrexate on both cell proliferation and antibody synthesis were completely reversed by the addition of high concentrations of exogenous folinic acid. The results suggest that methotrexate has effects on immunocompetent cells that may contribute to the efficacy of this drug in the treatment of RA and other autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784965     DOI: 10.1002/anr.1780320404

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 3.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

Review 4.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

5.  Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?

Authors:  L D Fairbanks; K Rückemann; Y Qiu; C M Hawrylowicz; D F Richards; R Swaminathan; B Kirschbaum; H A Simmonds
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

Review 6.  Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.

Authors:  Jing Liu; Jie Zhao; Liang Hu; Yuchun Cao; Bo Huang
Journal:  Cell Mol Immunol       Date:  2011-03-21       Impact factor: 11.530

7.  Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.

Authors:  Tim Niehues; Gerd Horneff; Hartmut Michels; Michaela Sailer Höck; Lothar Schuchmann
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

8.  Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation.

Authors:  R J Hine; M P Everson; J M Hardin; S L Morgan; G S Alarcòn; J E Baggott; W J Koopman; C L Krumdieck
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

9.  Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizoribine.

Authors:  S Hirohata; K Nakanishi; T Yanagida
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

10.  The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis.

Authors:  M J van der Veen; J W Bijlsma
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.